Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States.

GSK said last week it plans to file for approval of Jemperli in this setting in the first half of 2023, and if it gets the nod from regulators, the drug could claim a category of the endometrial ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are creating turbulence within the Pharma sector.

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...

GSK’s application is underpinned by the positive ... In January 2025, the European Commission approved the company’s Jemperli in conjunction with chemotherapy for the first-line treatment ...